Mingming Hu
5 Papers
Mingming Hu is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 3 publications.
Chat about Author
Papers
Comprehensive Comparative Molecular Characterization of Young and Old Lung Cancer Patients
Mingming Hu,Jinjing Tan,Zhentian Liu,Lifeng Li,Dan Zhao,Baolan Li,Xuan Gao,Nanying Che,Hongmei Zhang +8 more
TL;DR: Although young lung patients with NSCLC had better outcomes, there were still adverse factors of them, suggesting that the young group still needs more caution for treatment choice and monitoring after the treatment to further improve the prognosis.
Mutation status analysis of 58 patients with advanced ALK fusion gene positive non small cell lung cancer
Yuan Yang,Baohua Lu,Mingming Hu,Qunhui Wang,Mei Jiang,Hongmei Zhang,Zhe Liu +6 more
TL;DR: There are differences in abundance between different fusion partners and subtypes in advanced NSCLC with positive ALK, and OS is not associated with subtypes, mutation abundance and first line treatment option of either generation of ALK inhibitors.
2
Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer
Ying Wang,Yanxia Liu,Zhiyun Zhang,Baohua Lu,Yuan Gao,Li Tong,Mingming Hu,Peter Lin,Baolan Li,Hongmei Zhang +9 more
TL;DR: In this paper , the authors investigated the clinical utility of diverse aneuploid CTC subtypes and particularly CTC-associated white blood cell (CTC-WBC) clusters in predicting treatment response, prognosis and real-time monitoring disease progression in advanced driver gene-negative non-small lung cancer (NSCLC) patients.
Identification of a six-gene signature to predict survival and immunotherapy effectiveness of gastric cancer
Qi Wang,Biyuan Zhang,Haiji Wang,Mingming Hu,Hui Feng,Wen Gao,Haijun Lu,Ye-Kai Tan,Yinying Dong,Mingjin Xu,Tian-Hui Guo,Xiaomeng Ji +11 more
TL;DR: In this paper , a six-gene signature was used to predict the prognosis of Gastric cancer (GC) patients using LASSO regression and a prognostic model.
Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study.
Mingming Hu,Xiaomi Li,Haifeng Lin,Baohua Lu,Qunhui Wang,Li Tong,Hongxia Li,Nanying Che,Shaojun Hung,Yi Han,Kang Shi,Chenghai Li,Hongmei Zhang,Zhidong Liu,Tongmei Zhang +14 more
TL;DR: Favourable efficacy in operable NSCLC treated with NACI is revealed and the proposed model based on multiple clinically accessible parameters could effectively predict MPR probability and could be a powerful tool in personalized medication.